Veleanu, Maxime https://orcid.org/0000-0001-6760-3488
Schuberth, Louise https://orcid.org/0009-0005-1338-7261
Kilias, Antje https://orcid.org/0000-0001-6691-7194
Weber, Jakob
Warneke, Jan
Würz, Lovis
Schwär, Tim
Heck, Rebecca
Müller, Joelle
Sarrazin, David H. https://orcid.org/0000-0003-1326-3232
Anselin, Marguerite
Rutke, Lukas
Suarez Marchi, Guillermo https://orcid.org/0009-0005-6219-0174
Zimmermann, Stella https://orcid.org/0009-0007-9376-4120
Borgeest, Zoe
Balzinger, Martin
Blendinger, Alina
Catarata, Anna
Dib, Samira Assaad
Sych, Yaroslav https://orcid.org/0000-0002-1822-8631
Cholvin, Thibault https://orcid.org/0000-0002-9964-7693
Bartos, Marlene https://orcid.org/0000-0001-9741-1946
Domschke, Katharina https://orcid.org/0000-0002-2550-9132
Normann, Claus https://orcid.org/0000-0001-5693-8936
Vestring, Stefan https://orcid.org/0000-0001-9150-8712
Serchov, Tsvetan https://orcid.org/0000-0002-2234-2875
Funding for this research was provided by:
Berta-Ottenstein Program for Clinician Scientists, Faculty of Medicine, University of Freiburg, Germany.
Hans A. Krebs Medical Scientist Fellowship Program, University of Freiburg, Germany.
Deutsche Forschungsgemeinschaft (DFG NO370/7-1)
Deutsche Forschungsgemeinschaft (SE 2666/2-1)
Deutsche Forschungsgemeinschaft (SE 2666/2-3)
Centre National de la Recherche Scientifique (CNRS UPR3212)
Université de Strasbourg (2021-2028)
Article History
Received: 31 March 2025
Accepted: 17 August 2026
First Online: 1 September 2026
Ethics
competing interests: C.N., S.V., and K.D. received lecture fees and advisory board honoraria from Johnson & Johnson, the manufacturer of Esketamine. C.N. received research support as a principal investigator in clinical trials sponsored by Johnson & Johnson. C.N. received honoraria as a member of a DMC board by Novartis. T.Serchov. received honoraria consulting Primetime Life Sciences, LLC. All other authors declare that they have no competing interests.